A reversible monoamine oxidase a inhibitor, befloxatone: structural approach of its mechanism of action

Moureau, Florence; Evrard, G.; Koenig, Jean Jacques; Jegham, Samir; George, Pascal; Durant, François

doi:10.1016/s0968-0896(99)00102-9

Cited by 72 publications

(34 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 11 C]Befloxatone was displaced in a dose-dependent manner, confirming the reversible interaction of befloxatone with MAO-A demonstrated in vitro (Curet et al, 1996;Wouters et al, 1999). In our study, we found that the estimated dose of befloxatone needed to displace half of the specifically bound radioactivity in brain is very low (about 0.02 mg/kg).…”

Section: Befloxatone In Vivo By Pet 471supporting

confidence: 87%

See 1 more Smart Citation

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹C]Befloxatone

Bottlaender¹,

Dollé²,

Guenther³

et al. 2003

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

Section: Befloxatone In Vivo By Pet 471supporting

confidence: 87%

“…Befloxatone, an oxazolidinone derivative, is a selective MAO-A reversible inhibitor with potential antidepressant properties Rovei et al, 1994;Wouters et al, 1999). The biochemical and pharmacological profiles of befloxatone were extensively studied in rats and in human tissues (Caille et al, 1996;Curet et al, 1996).…”

mentioning

confidence: 99%

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹C]Befloxatone

Bottlaender¹,

Dollé²,

Guenther³

et al. 2003

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

“…The final conclusion suggests that electron-rich rings systems and higher HOMO levels increased the potency of these derivatives against MAO-A enzyme. The results are in agreement with some studies suggesting the existence of charge-transfer interactions between inhibitors and the FAD cofactor of MAO enzymes [77,99,100]. A previous study carried out in phenylalkylamines also revealed that electronic descriptors had an important contribution in the development of the QSAR model [83].…”

Section: Qsar With 3d Descriptorssupporting

confidence: 91%

Predicting Monoamine Oxidase Inhibitory Activity Through Ligand-Based Models

Vilar¹,

Ferino²,

Quezada³

et al. 2013

CTMC

View full text Add to dashboard Cite

The evolution of bio-and cheminformatics associated with the development of specialized software and increasing computer power has produced a great interest in theoretical in silico methods applied in drug rational design. These techniques apply the concept that "similar molecules have similar biological properties" that has been exploited in Medicinal Chemistry for years to design new molecules with desirable pharmacological profiles. Ligand-based methods are not dependent on receptor structural data and take into account two and three-dimensional molecular properties to assess similarity of new compounds in regards to the set of molecules with the biological property under study. Depending on the complexity of the calculation, there are different types of ligand-based methods, such as QSAR (Quantitative Structure-Activity Relationship) with 2D and 3D descriptors, CoMFA (Comparative Molecular Field Analysis) or pharmacophoric approaches. This work provides a description of a series of ligand-based models applied in the prediction of the inhibitory activity of monoamine oxidase (MAO) enzymes. The controlled regulation of the enzymes' function through the use of MAO inhibitors is used as a treatment in many psychiatric and neurological disorders, such as depression, anxiety, Alzheimer's and Parkinson's disease. For this reason, multiple scaffolds, such as substituted coumarins, indolylmethylamine or pyridazine derivatives were synthesized and assayed toward MAO-A and MAO-B inhibition. Our intention is to focus on the description of ligand-based models to provide new insights in the relationship between the MAO inhibitory activity and the molecular structure of the different inhibitors, and further study enzyme selectivity and possible mechanisms of action.

show abstract

“…These include the RNA binding agent 131 [109], antithrombotic agent 132 [110], antipsychotic agent panamesine 133 [111], and they are MAO-A inhibitors [112][113][114][115]. Toloxatone 134 and Befloxatone 135 [113][114] are reversible MAO-A inhibitors, and are useful as antidepressant agents.…”

Section: Oxazolidinone Derivatives With Other Biological Activitiesmentioning

confidence: 99%

“…Toloxatone 134 and Befloxatone 135 [113][114] are reversible MAO-A inhibitors, and are useful as antidepressant agents. Another pyrrolyl oxazolidinone derivative 136 is a potent highly selective MAO-A inhibitor [115].…”

Section: Oxazolidinone Derivatives With Other Biological Activitiesmentioning

confidence: 99%

Synthesis and Antibacterial Properties of Oxazolidinones and Oxazinanones

Wang¹

2008

AIAMC

View full text Add to dashboard Cite

Oxazolidinones are important synthetic antibacterial agents useful for the treatment of multi antibiotic resistant Gram-positive bacterial infections. Since the launch of Linezolid, the first member of the oxazolidinone antibacterial family, there have been many studies directed towards structural optimization and the development of second generation oxazolidinones. The N-aryl 5-acetamido methyl oxazolidinone is the core structure for this class of antibacterial agents and the oxazolidinone component is essential for antibacterial activities. The chiral cyclic carbamate 5-hydroxymethyloxazolidin-2-one and 6-hydroxymethyl-[1,3]oxazinan-2-one are also important building blocks for synthesizing other biologically active compounds. Because of the importance of these compounds, many methods have been developed for their facile syntheses. In the first part of this paper, the synthesis of Linezolid and its analogs, as well as the preparation of the oxazolidinone core structures, will be reviewed. Secondly, recent developments in the area of oxazolidinone antibacterial agents including structure-activity relationships will be reviewed.

show abstract

A reversible monoamine oxidase a inhibitor, befloxatone: structural approach of its mechanism of action

Cited by 72 publications

References 24 publications

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹C]Befloxatone

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹C]Befloxatone

Predicting Monoamine Oxidase Inhibitory Activity Through Ligand-Based Models

Synthesis and Antibacterial Properties of Oxazolidinones and Oxazinanones

Contact Info

Product

Resources

About

A reversible monoamine oxidase a inhibitor, befloxatone: structural approach of its mechanism of action

Cited by 72 publications

References 24 publications

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone

Predicting Monoamine Oxidase Inhibitory Activity Through Ligand-Based Models

Synthesis and Antibacterial Properties of Oxazolidinones and Oxazinanones

Contact Info

Product

Resources

About

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹C]Befloxatone

Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [¹¹C]Befloxatone